BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1861081)

  • 1. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalently-bound human C4b dimers consisting of C4B isotype show higher hemolytic activity than those of C4A in the C3-bypass complement pathway.
    Masaki T; Matsumoto M; Hara T; Nakanishi I; Kitamura H; Seya T
    Mol Immunol; 1995 Jan; 32(1):21-6. PubMed ID: 7870055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
    Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
    J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
    Gigli I; Sorvillo J; Halbwachs-Mecarelli L
    J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
    Thielens NM; Colomb MG
    Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the involvement of arginine 462 and the flanking sequence of human C4 beta-chain in mediating C5 binding to the C4b subcomponent of the classical complement pathway C5 convertase.
    Ebanks RO; Isenman DE
    J Immunol; 1995 Mar; 154(6):2808-20. PubMed ID: 7876551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
    J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
    Saint-Remy JM
    Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
    Kinoshita T; Dodds AW; Law SK; Inoue K
    Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid residues 1101-1105 of the isotypic region of human C4B is important to the covalent binding activity of complement component C4.
    Reilly BD; Levine RP; Skanes VM
    J Immunol; 1991 Nov; 147(9):3018-23. PubMed ID: 1919003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The binding of human complement component C4 to antibody-antigen aggregates.
    Campbell RD; Dodds AW; Porter RR
    Biochem J; 1980 Jul; 189(1):67-80. PubMed ID: 6906229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.